Why the study?
Myocardial fibrosis involves interactions among activated fibroblasts, immune cells, and metabolic signals, and whether kaempferol attenuates Ang II-induced fibrosis via macrophage PKM2/HIF-1α-linked glycolytic and inflammatory activation was evaluated.
Population
Male C57BL/6J mice across primary (n=48), dose-response (n=48), exposure (n=42), and macrophage donor (n=6) cohorts
Comparison
Kaempferol (2.5, 5, and 10 mg/kg/day) vs Ang II + vehicle and losartan comparator
Design
Randomized experimental in vivo mouse study and in vitro macrophage study
Follow-up
28 days
Answers are grounded in this paper and cite their sources.
Shows kaempferol reduces cardiac fibrosis and improves heart function in mice exposed to angiotensin II, indicating potential cardioprotection via suppression of macrophage glycolytic signaling.
Introduction Myocardial fibrosis develops through sustained interactions among activated fibroblasts, infiltrating immune cells, and metabolic signals within the injured myocardium. This study evaluated whether kaempferol attenuated angiotensin II (Ang II)-induced myocardial fibrosis in association with changes in macrophage pyruvate kinase M2 (PKM2)/hypoxia-inducible factor 1α (HIF-1α)-linked glycolytic and inflammatory activation. Methods The primary in vivo cohort comprised 48 male C57BL/6J mice randomized to four groups (12 per group) and treated for 28 days. Separate exploratory cohorts comprised 48 mice assigned to a dose-response/positive-comparator study and 42 mice assigned to single-dose plasma and myocardial exposure profiling. Donor-matched bone marrow-derived macrophages from six additional mice were studied under eight conditions incorporating kaempferol, PKM2 overexpression, Pkm2 knockdown, and matched controls. Results In the primary cohort, kaempferol reduced interstitial collagen volume fraction from 16.07% ± 2.10% to 9.14% ± 2.26% and increased left ventricular ejection fraction from 48.01% ± 2.97% to 56.87% ± 2.56%. In the separate dose-response cohort, collagen volume fraction declined from 16.00% ± 2.10% with Ang II + vehicle to 13.70% ± 1.90%, 11.20% ± 1.80%, and 9.20% ± 2.00% with kaempferol at 2.5, 5, and 10 mg/kg/day, respectively; the losartan comparator group had a value of 8.60% ± 1.70%. Plasma kaempferol concentration was highest at the 0.5-h sampling point and myocardial concentration at 1 h after a single 10 mg/kg intraperitoneal dose. In macrophages, kaempferol reduced glycolytic and inflammatory readouts and weakened conditioned-medium-induced fibroblast activation. Fibroblast protein measurements showed partial restoration of α-smooth muscle actin (α-SMA) and collagen I abundance with PKM2 overexpression and lower abundance after Pkm2 knockdown. Discussion These findings support an antifibrotic action associated with reduced inflammatory macrophage enrichment and suppression of PKM2/HIF-1α-linked glycolytic activation, while not establishing PKM2 as a direct kaempferol target or the pathway as the sole mediator of cardioprotection. Because kaempferol may exhibit assay-dependent interference or nonspecific biological effects, the in vitro findings and putative pathway involvement require cautious interpretation; the available data do not demonstrate direct PKM2 engagement or clinical efficacy.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: